Document is current
Any future updates will be listed below
-
Authors
Staszewsky, Lidia
Meessen, Jennifer M. T. A.
Novelli, Deborah
Wienhues-Thelen, Ursula-Henrike
Disertori, Marcello
Maggioni, Aldo P.
Masson, Serge
Tognoni, Gianni
Franzosi, Maria Grazia
Lucci, Donata
Latini, Roberto
-
Funding
Funding for this research was provided by:
Roche Diagnostics GmbH Penzberg, Germany.
Roche Diagnostics International Ltd, Rotkreuz, Switzerland
- License Information
-
More Information
Article History
Received: 24 May 2021
Accepted: 2 November 2021
First Online: 19 November 2021
Declarations
:
: The GISSI-AF trial complied with all the relevant national regulations, and with the Declaration of Helsinki. The study was conducted with the approval of the local ethics committees from the 36 Italian clinical centers that participated in the biomarkers and echocardiographic substudy of the GISSI-AF trial (Additional file : Appendix 3 Participating centers and investigators). All participants provided written informed consent.
: Not applicable.
: LS, APM, MGF, MD, DL, GT and RL received institutional research support from Novartis Pharma and Roche Diagnostics. JM and DN received institutional research support from Roche Diagnostics. UHW-T is an employee of Roche Diagnostics GmbH, Penzberg, Germany, the company that funded part of the present study. SM is currently an employee at Roche Diagnostics International, Rotkreuz, Switzerland.
